KR102580378B1 - 릴루졸의 설하 제제 - Google Patents

릴루졸의 설하 제제 Download PDF

Info

Publication number
KR102580378B1
KR102580378B1 KR1020177016906A KR20177016906A KR102580378B1 KR 102580378 B1 KR102580378 B1 KR 102580378B1 KR 1020177016906 A KR1020177016906 A KR 1020177016906A KR 20177016906 A KR20177016906 A KR 20177016906A KR 102580378 B1 KR102580378 B1 KR 102580378B1
Authority
KR
South Korea
Prior art keywords
delete delete
riluzole
sublingual
disorder
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177016906A
Other languages
English (en)
Korean (ko)
Other versions
KR20170137032A (ko
Inventor
블라디미르 코릭
로버트 엠. 버만
로날드 사무엘 블라디카
암가드 살레
대니 유
Original Assignee
바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. filed Critical 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디.
Priority to KR1020237031525A priority Critical patent/KR102811263B1/ko
Publication of KR20170137032A publication Critical patent/KR20170137032A/ko
Application granted granted Critical
Publication of KR102580378B1 publication Critical patent/KR102580378B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177016906A 2014-11-21 2015-11-17 릴루졸의 설하 제제 Active KR102580378B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237031525A KR102811263B1 (ko) 2014-11-21 2015-11-17 릴루졸의 설하 제제

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462083094P 2014-11-21 2014-11-21
US62/083,094 2014-11-21
PCT/US2015/061114 WO2016081472A1 (en) 2014-11-21 2015-11-17 Sublingual formulation of riluzole

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237031525A Division KR102811263B1 (ko) 2014-11-21 2015-11-17 릴루졸의 설하 제제

Publications (2)

Publication Number Publication Date
KR20170137032A KR20170137032A (ko) 2017-12-12
KR102580378B1 true KR102580378B1 (ko) 2023-09-19

Family

ID=55085882

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177016906A Active KR102580378B1 (ko) 2014-11-21 2015-11-17 릴루졸의 설하 제제
KR1020237031525A Active KR102811263B1 (ko) 2014-11-21 2015-11-17 릴루졸의 설하 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237031525A Active KR102811263B1 (ko) 2014-11-21 2015-11-17 릴루졸의 설하 제제

Country Status (24)

Country Link
US (3) US11660267B2 (OSRAM)
EP (3) EP4039247B1 (OSRAM)
JP (3) JP6753860B2 (OSRAM)
KR (2) KR102580378B1 (OSRAM)
CN (1) CN107249567B (OSRAM)
AU (2) AU2015350148B2 (OSRAM)
BR (1) BR112017010423B1 (OSRAM)
CA (1) CA2967662A1 (OSRAM)
CY (1) CY1122469T1 (OSRAM)
DK (1) DK3220891T3 (OSRAM)
EA (1) EA038518B1 (OSRAM)
ES (2) ES2751300T3 (OSRAM)
HR (1) HRP20191892T8 (OSRAM)
HU (1) HUE046869T2 (OSRAM)
IL (2) IL278188B2 (OSRAM)
LT (1) LT3220891T (OSRAM)
MX (1) MX368838B (OSRAM)
PH (1) PH12017500934B1 (OSRAM)
PL (1) PL3220891T3 (OSRAM)
PT (1) PT3220891T (OSRAM)
RS (1) RS59490B1 (OSRAM)
SG (1) SG11201703896QA (OSRAM)
SI (1) SI3220891T1 (OSRAM)
WO (1) WO2016081472A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3038979A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP3755332A1 (en) * 2018-02-21 2020-12-30 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
JP2021525714A (ja) * 2018-05-27 2021-09-27 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． 疾患の処置のためのリルゾール口腔内崩壊錠の使用
JP2021534160A (ja) * 2018-08-16 2021-12-09 バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. 疾患処置のためのリルゾール口腔内崩壊錠の使用
MX2022004808A (es) * 2019-10-22 2022-06-08 Arvinas Operations Inc Métodos para tratar el cáncer de próstata.
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
WO2022103636A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN113876735B (zh) * 2021-10-20 2023-05-12 陇南市第一人民医院 一种利鲁唑微球制剂及其制备方法
KR102625977B1 (ko) 2021-11-24 2024-01-17 부산대학교 산학협력단 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물
WO2025122895A1 (en) 2023-12-08 2025-06-12 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520254A (ja) * 2009-03-13 2012-09-06 イタルファルマコ ソシエタ ペル アチオニ リルゾール水性懸濁液

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
WO1995001782A2 (en) 1993-07-09 1995-01-19 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
DK0946111T3 (da) * 1996-12-20 2004-06-21 Nutrinova Gmbh Fremgangsmåde til forstærkning af sødekraften og til smagsforbedring af en blanding af højintensive sødestoffer
DE69840495D1 (de) 1997-02-20 2009-03-12 Massachusetts Inst Technology Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
JP4947833B2 (ja) 1997-07-25 2012-06-06 アルペックス・ファルマ・ソシエテ・アノニム 速崩壊性口内溶解錠の製造に適した顆粒の製造方法
US7939105B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
AU2173400A (en) * 1998-12-09 2000-06-26 Chiron Corporation Method for administering agents to the central nervous system
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
JP2001328947A (ja) * 2000-05-19 2001-11-27 Ritsuko Senba 脳由来神経栄養因子発現促進剤
US6432992B1 (en) * 2000-06-05 2002-08-13 Aventis Pharm Sa Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
EP1443912B1 (en) 2001-10-12 2007-08-29 Elan Pharma International Limited Compositions having a combination of immediate release and controlled release characteristics
WO2003068604A1 (en) 2002-02-13 2003-08-21 Weibel Michael K Drug dose-form and method of manufacture
CA2477088A1 (en) * 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2004105756A2 (en) * 2003-05-29 2004-12-09 Novartis Ag Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
BRPI0620578A2 (pt) 2005-12-27 2011-12-06 Jubilant Organosys Ltd composição farmacêutica que dissolve na boca e processo para o preparo da mesma
GB0625322D0 (en) * 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
EP1980240A1 (en) * 2007-04-11 2008-10-15 Cephalon France Lyophilized pharmaceutical compositions and methods of making and using same
EP2170282A4 (en) 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION
WO2010009279A1 (en) * 2008-07-15 2010-01-21 University Of Medicine And Dentistry Of New Jersey Methods and compositions for treating alzheimer's disease
US8414356B2 (en) 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8545806B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
WO2010096869A1 (en) * 2009-02-26 2010-09-02 Steven Michael Weiss An agent for improving inotropy and lusitropy, and for treating diseases causing or caused by poor contractility or relaxation of the heart
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
TR201809351T4 (tr) * 2011-03-01 2018-07-23 Pharnext Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi.
UA113165C2 (xx) * 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
WO2013010015A2 (en) * 2011-07-13 2013-01-17 Cytokinetics, Inc. Combination als therapy
CA2864008C (en) * 2012-03-01 2020-04-21 Pharnext New compositions for treating amyotrophic lateral sclerosis
EA201791110A1 (ru) 2014-11-21 2017-11-30 Биохэвен Фармасьютикэл Холдинг Компани Лтд. Сублингвальное введение рилузола
RS62915B1 (sr) * 2015-03-03 2022-03-31 Biohaven Therapeutics Ltd Prolekovi riluzola i njihova primena

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520254A (ja) * 2009-03-13 2012-09-06 イタルファルマコ ソシエタ ペル アチオニ リルゾール水性懸濁液

Also Published As

Publication number Publication date
EP3616686B1 (en) 2021-05-19
ES2751300T3 (es) 2020-03-31
HUE046869T2 (hu) 2020-04-28
LT3220891T (lt) 2019-11-11
EA201790958A1 (ru) 2018-01-31
IL278188A (en) 2020-11-30
DK3220891T3 (da) 2019-11-04
AU2021201034B2 (en) 2023-07-06
KR20230135183A (ko) 2023-09-22
MX368838B (es) 2019-10-18
US20180153794A1 (en) 2018-06-07
JP2017535613A (ja) 2017-11-30
PH12017500934A1 (en) 2017-11-20
EP3220891A1 (en) 2017-09-27
IL252285B (en) 2020-10-29
HRP20191892T8 (hr) 2020-09-18
IL252285A0 (en) 2017-07-31
BR112017010423B1 (pt) 2023-09-26
RS59490B1 (sr) 2019-12-31
AU2021201034A1 (en) 2021-03-11
EP4039247A2 (en) 2022-08-10
CN107249567A (zh) 2017-10-13
US20250114301A1 (en) 2025-04-10
PH12017500934B1 (en) 2024-06-28
AU2015350148B2 (en) 2020-11-26
CN107249567B (zh) 2021-08-03
MX2017006446A (es) 2018-02-12
US20210038499A1 (en) 2021-02-11
IL278188B1 (en) 2024-11-01
EP3616686A1 (en) 2020-03-04
ES2882783T3 (es) 2021-12-02
HRP20191892T1 (hr) 2020-01-10
EP4039247A3 (en) 2022-11-16
EA038518B1 (ru) 2021-09-09
AU2015350148A1 (en) 2017-06-15
EP3220891B1 (en) 2019-07-24
KR102811263B1 (ko) 2025-05-23
BR112017010423A2 (pt) 2017-12-26
SI3220891T1 (sl) 2020-02-28
KR20170137032A (ko) 2017-12-12
IL278188B2 (en) 2025-03-01
PT3220891T (pt) 2019-10-31
US12121609B2 (en) 2024-10-22
US11660267B2 (en) 2023-05-30
JP2023065398A (ja) 2023-05-12
EP3616686B8 (en) 2021-06-23
WO2016081472A1 (en) 2016-05-26
EP4039247B1 (en) 2025-11-05
CY1122469T1 (el) 2021-01-27
PL3220891T3 (pl) 2020-08-24
SG11201703896QA (en) 2017-06-29
JP6753860B2 (ja) 2020-09-09
CA2967662A1 (en) 2016-05-26
JP2021001173A (ja) 2021-01-07

Similar Documents

Publication Publication Date Title
KR102580378B1 (ko) 릴루졸의 설하 제제
EP3220890A1 (en) Sublingual administration of riluzole
AU2014249534B2 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
AU2014249530B2 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
HK40077183A (en) Sublingual formulation of riluzole
HK40024978A (en) Sublingual formulation of riluzole
HK40024978B (en) Sublingual formulation of riluzole
HK1243318B (en) Sublingual formulation of riluzole
HK1243318A1 (en) Sublingual formulation of riluzole

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301